Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of Waldenstrom's macroglobulinemia confirmed by IgM gammopathy and bone marrow biopsy
• * Presence of lymphoplasmacytic cells
• * CD20+ plasma cell dyscrasia on the majority of malignant cells
• * Bone marrow involvement of 20-50% by core needle biopsy of at least 1.5 cm in length
• Clinical indication for initiation of treatment, including 1 or more of the following characteristics:
• * Symptoms associated with the disease (e.g., fatigue, asthenia, or painful adenopathy)
• * Anemia
• * IgM greater than 3 g/L
• * Progression as indicated by a rate of IgM rise of more than 0.5 g over 6 months
• No myelodysplastic syndromes or profound hypocellularity of the bone marrow
• PATIENT CHARACTERISTICS:
• Age
• Over 18
• Performance status
• WHO 0-2
• Life expectancy
• More than 3 months
• Hematopoietic
• Absolute neutrophil count greater than 1,500/mm\^3
• Total B-lymphocyte count less than 5,000/mm\^3
• Platelet count greater than 100,000/mm\^3
• No hyperviscosity syndrome
• Hepatic
• Bilirubin no greater than 1.5 mg/dL
• Renal
• Not specified
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 1 year after study completion
• No uncontrolled CNS disease
• No serious nonmalignant disease that would preclude study participation
• No other concurrent active malignancy except controlled skin cancer or prostate cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
• More than 4 months since prior rituximab
• No prior radioimmunotherapy
• Chemotherapy
• No prior high-dose chemotherapy (unless patient has had prior back-up stem cell collections)
• More than 6 weeks since prior chemotherapy
• Endocrine therapy
• More than 4 weeks since prior corticosteroids
• Radiotherapy
• No prior radiotherapy
• Surgery
• Not specified